FDA approves immunotherapy regimen for advanced liver cancer

The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.The combination of atezolizumab (Tecentriq, Genentech) — a monoclonal antibody designed to bind with PD-L1 — and bevacizumab (Avastin, Genentech) is the only cancer immunotherapy regimen approved for this patient population.“We’re excited that [this] approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancerRead More

Share on facebook
Share on twitter
Share on linkedin